A Trial of AMG 479, Everolimus (RAD001) and Panitumumab in Patients With Advanced Cancer - QUILT-3.007
Status:
Completed
Trial end date:
2018-12-19
Target enrollment:
Participant gender:
Summary
This open-label, non-randomized, dose escalation phase I biomarker trial of the triplet
regimen of AMG 479, everolimus, and panitumumab for subjects with refractory advanced solid
tumors is designed to assess the safety and tolerability of this combination as well as
preliminary efficacy.